Handel Eiger Biopharma - EIGR CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | - | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | N/A |
Åben* | N/A |
1-Års Ændring* | N/A |
Dagens Spænd* | N/A |
52-Ugers Spænd | 0.95-9.92 |
Gennemsnitlig Volumen (10 dage) | 462.01K |
Gennemsnitlig Volumen (3 måneder) | 15.31M |
Market Cap | 42.80M |
P/E-forhold | -100.00K |
Udestående aktier | 44.16M |
Omsætning | 13.48M |
EPS | -2.34 |
Dividend (Udbytte %) | N/A |
Beta | 2.02 |
Næste indtjeningsopgørelse | May 3, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|
Eiger Biopharma Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total omsætning | 12.142 | 0 | 0 | 0 | 0 |
Omsætning | 12.142 | 0 | |||
Totale Driftsudgifter | 89.081 | 62.149 | 68.904 | 51.047 | 41.52 |
Salgs/Generelle/Admin. Udgifter, Total | 23.9 | 20.559 | 17.113 | 13.956 | 12.001 |
Forskning & Udvikling | 64.436 | 41.59 | 51.791 | 37.091 | 29.519 |
Driftsindtægter | -76.939 | -62.149 | -68.904 | -51.047 | -41.52 |
Renteindkomst (Udgift), Netto Ikke-Drift | -3.401 | -2.89 | -1.333 | -1.332 | -1.114 |
Andre, Netto | 46.487 | -0.012 | -0.015 | -0.012 | 0.186 |
Netto Indkomst Før Skat | -33.853 | -65.051 | -70.252 | -52.391 | -42.448 |
Netto Indkomst Efter Skat | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Netto Indkomst Før Ekstra Ting | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Netto Indkomst | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Fortyndet Netto Indkomst | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Fortyndet Vægtet Gennemsnit Aktier | 33.9443 | 28.1434 | 22.7856 | 13.711 | 8.72794 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.99919 | -2.31141 | -3.08317 | -3.82108 | -4.86346 |
Fortyndet Normaliseret EPS | -0.99919 | -2.31141 | -3.08317 | -3.82108 | -4.86346 |
Kost af omsætning, Total | 0.745 | ||||
Bruttofortjeneste | 11.397 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total omsætning | 2.673 | 3.36 | 3.039 | 2.097 | 3.646 |
Omsætning | 2.673 | 3.36 | 3.039 | 2.097 | 3.646 |
Kost af omsætning, Total | 0.11 | 0.104 | 0.318 | 0.27 | 0.053 |
Bruttofortjeneste | 2.563 | 3.256 | 2.721 | 1.827 | 3.593 |
Totale Driftsudgifter | 24.493 | 24.274 | 24.89 | 20.458 | 19.459 |
Salgs/Generelle/Admin. Udgifter, Total | 6.813 | 5.984 | 6.466 | 5.886 | 5.564 |
Forskning & Udvikling | 17.57 | 18.186 | 18.106 | 14.302 | 13.842 |
Driftsindtægter | -21.82 | -20.914 | -21.851 | -18.361 | -15.813 |
Renteindkomst (Udgift), Netto Ikke-Drift | -0.841 | -0.861 | -0.859 | -0.847 | -0.834 |
Gain (Loss) on Sale of Assets | 0 | 0 | 46.5 | ||
Andre, Netto | 0.027 | 0.025 | 0.503 | 0.045 | -0.586 |
Netto Indkomst Før Skat | -22.634 | -21.75 | -22.207 | -19.163 | 29.267 |
Netto Indkomst Efter Skat | -22.643 | -21.768 | -22.223 | -19.174 | 29.248 |
Netto Indkomst Før Ekstra Ting | -22.643 | -21.768 | -22.223 | -19.174 | 29.248 |
Netto Indkomst | -22.643 | -21.768 | -22.223 | -19.174 | 29.248 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -22.643 | -21.768 | -22.223 | -19.174 | 29.248 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -22.643 | -21.768 | -22.223 | -19.174 | 29.248 |
Fortyndet Netto Indkomst | -22.643 | -21.768 | -22.223 | -19.174 | 29.248 |
Fortyndet Vægtet Gennemsnit Aktier | 35.2532 | 34.0111 | 33.9466 | 33.9321 | 34.2209 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.6423 | -0.64003 | -0.65465 | -0.56507 | 0.85468 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.6423 | -0.64003 | -0.65465 | -0.56507 | -0.02855 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 103.364 | 137.806 | 100.384 | 101.845 | 42.491 |
Likvider og Kortsigtede Investeringer | 88.815 | 128.84 | 94.994 | 100.353 | 41.779 |
Likvider & Lignende | 22.221 | 28.864 | 39.373 | 61.262 | 32.035 |
Kortsigtede Investeringer | 66.594 | 99.976 | 55.621 | 39.091 | 9.744 |
Prepaid Expenses | 9.361 | 8.966 | 5.39 | 1.492 | 0.712 |
Total Assets | 126.402 | 143.594 | 105.139 | 102.448 | 42.882 |
Property/Plant/Equipment, Total - Net | 1.266 | 1.885 | 2.244 | 0.167 | 0.079 |
Property/Plant/Equipment, Total - Gross | 1.869 | 2.227 | 2.458 | 0.328 | 0.186 |
Accumulated Depreciation, Total | -0.603 | -0.342 | -0.214 | -0.161 | -0.107 |
Other Long Term Assets, Total | 4.51 | 3.903 | 2.511 | 0.436 | 0.312 |
Total Current Liabilities | 29.901 | 16.627 | 16.949 | 10.024 | 7.269 |
Accounts Payable | 7.765 | 4.64 | 6.414 | 5.83 | 3.183 |
Accrued Expenses | 14.327 | 11.987 | 10.535 | 4.194 | 2.084 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 54.003 | 48.559 | 48.659 | 35.856 | 20.36 |
Total Long Term Debt | 23.986 | 31.194 | 30.39 | 25.62 | 13.091 |
Long Term Debt | 23.986 | 31.194 | 30.39 | 25.62 | 13.091 |
Other Liabilities, Total | 0.116 | 0.738 | 1.32 | 0.212 | |
Total Equity | 72.399 | 95.035 | 56.48 | 66.592 | 22.522 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.035 | 0.034 | 0.024 | 0.019 | 0.011 |
Additional Paid-In Capital | 412.93 | 401.509 | 297.863 | 237.795 | 141.32 |
Retained Earnings (Accumulated Deficit) | -340.417 | -306.5 | -241.449 | -171.197 | -118.806 |
Other Equity, Total | -0.149 | -0.008 | 0.042 | -0.025 | -0.003 |
Total Liabilities & Shareholders’ Equity | 126.402 | 143.594 | 105.139 | 102.448 | 42.882 |
Total Common Shares Outstanding | 34.5688 | 33.8785 | 24.5234 | 19.2118 | 10.5266 |
Current Port. of LT Debt/Capital Leases | 7.809 | 0 | 2.002 | ||
Totale Tilgodehavender, Netto | 2.576 | ||||
Accounts Receivable - Trade, Net | 2.576 | ||||
Total Inventory | 2.612 | ||||
Long Term Investments | 17.262 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 147.356 | 103.364 | 99.086 | 118.803 | 169.886 |
Likvider og Kortsigtede Investeringer | 132.717 | 88.815 | 85.306 | 107.367 | 160.492 |
Likvider & Lignende | 46.562 | 22.221 | 49.255 | 65.056 | 108.41 |
Kortsigtede Investeringer | 86.155 | 66.594 | 36.051 | 42.311 | 52.082 |
Totale Tilgodehavender, Netto | 2.287 | 2.576 | 2.762 | 1.438 | 0.639 |
Accounts Receivable - Trade, Net | 2.287 | 2.576 | 2.762 | 1.438 | 0.639 |
Total Inventory | 1.91 | 2.612 | 2.621 | 2.065 | 1.397 |
Prepaid Expenses | 10.442 | 9.361 | 8.397 | 7.933 | 7.358 |
Total Assets | 153.329 | 126.402 | 140.277 | 156.838 | 175.515 |
Property/Plant/Equipment, Total - Net | 1.066 | 1.266 | 1.358 | 1.524 | 1.708 |
Other Long Term Assets, Total | 4.907 | 4.51 | 4.74 | 4.085 | 3.921 |
Total Current Liabilities | 36.612 | 29.901 | 22.012 | 15.875 | 17.517 |
Accounts Payable | 9.218 | 7.765 | 6.753 | 4.444 | 7.747 |
Accrued Expenses | 14.845 | 14.327 | 12.187 | 11.431 | 9.77 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 56.062 | 54.003 | 50.812 | 47.713 | 49.325 |
Total Long Term Debt | 19.446 | 23.986 | 28.524 | 31.403 | 31.218 |
Long Term Debt | 19.446 | 23.986 | 28.524 | 31.403 | 31.218 |
Other Liabilities, Total | 0.004 | 0.116 | 0.276 | 0.435 | 0.59 |
Total Equity | 97.267 | 72.399 | 89.465 | 109.125 | 126.19 |
Common Stock | 0.041 | 0.035 | 0.034 | 0.034 | 0.034 |
Additional Paid-In Capital | 460.808 | 412.93 | 408.079 | 405.523 | 403.413 |
Retained Earnings (Accumulated Deficit) | -363.06 | -340.417 | -318.649 | -296.426 | -277.252 |
Other Equity, Total | -0.522 | -0.149 | 0.001 | -0.006 | -0.005 |
Total Liabilities & Shareholders’ Equity | 153.329 | 126.402 | 140.277 | 156.838 | 175.515 |
Total Common Shares Outstanding | 40.5298 | 34.5688 | 33.9758 | 33.9513 | 33.9513 |
Long Term Investments | 0 | 17.262 | 35.093 | 32.426 | |
Current Port. of LT Debt/Capital Leases | 12.549 | 7.809 | 3.072 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -33.917 | -65.051 | -70.252 | -52.391 | -42.448 |
Likvider Fra Driftsaktiviteter | -71.342 | -63.185 | -63.614 | -42.671 | -38.372 |
Likvider Fra Driftsaktiviteter | 0.276 | 0.167 | 0.068 | 0.054 | 0.041 |
Ikke-Likvide Ting | -36.079 | 7.596 | 6.579 | 5.601 | 4.356 |
Ændringer i Driftskapital | -1.622 | -5.897 | -0.009 | 4.065 | -0.321 |
Likvider fra Investeringsaktiviteter | 61.532 | -44.787 | -16.471 | -29.085 | 22.657 |
Kapitaludgifter | -0.225 | -0.258 | -0.475 | -0.142 | -0.044 |
Andre Investerings-Cash-Flow-Ting, Total | 61.757 | -44.529 | -15.996 | -28.943 | 22.701 |
Likvider fra Financieringsaktiviteter | 3.167 | 97.463 | 58.196 | 100.983 | 19.994 |
Udstedelse (Pensionering) af Aktier, Netto | 3.658 | 97.485 | 54.168 | 91.048 | 19.994 |
Udstedelse (Pensionering) af Gæld, Netto | -0.175 | 0 | 4.96 | 9.935 | |
Netto Ændring i Likviditet | -6.643 | -10.509 | -21.889 | 29.227 | 4.279 |
Likvid Rente Betalt | 2.783 | 2.791 | 2.638 | 1.652 | |
Financiering af Cash-Flow-Ting | -0.316 | -0.022 | -0.932 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -22.643 | -33.917 | -12.149 | 10.074 | 29.248 |
Cash From Operating Activities | -18.459 | -71.342 | -54.577 | -35.317 | -14.933 |
Cash From Operating Activities | 0.073 | 0.276 | 0.203 | 0.135 | 0.067 |
Non-Cash Items | 2.728 | -36.079 | -38.755 | -41.767 | -44.374 |
Cash Interest Paid | 0.686 | 2.783 | 2.082 | 1.38 | 0.686 |
Changes in Working Capital | 1.383 | -1.622 | -3.876 | -3.759 | 0.126 |
Cash From Investing Activities | -3.002 | 61.532 | 74.865 | 71.566 | 94.464 |
Capital Expenditures | 0 | -0.225 | -0.092 | -0.092 | -0.016 |
Other Investing Cash Flow Items, Total | -3.002 | 61.757 | 74.957 | 71.658 | 94.48 |
Cash From Financing Activities | 45.802 | 3.167 | 0.103 | -0.057 | 0.015 |
Financing Cash Flow Items | -0.016 | -0.316 | -0.208 | -0.184 | -0.122 |
Issuance (Retirement) of Stock, Net | 45.818 | 3.658 | 0.486 | 0.302 | 0.312 |
Issuance (Retirement) of Debt, Net | 0 | -0.175 | -0.175 | -0.175 | -0.175 |
Net Change in Cash | 24.341 | -6.643 | 20.391 | 36.192 | 79.546 |
Cash Taxes Paid | 0.041 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 11.4957 | 5076343 | -2997954 | 2022-12-31 | LOW |
683 Capital Management LLC | Hedge Fund | 7.0541 | 3115000 | -1214751 | 2022-12-31 | MED |
Arkin (Moshe) | Individual Investor | 6.1438 | 2713002 | 886776 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.9101 | 2609825 | 101472 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.671 | 2062621 | 32038 | 2022-12-31 | LOW |
Propel Bio Partners L.P. | Venture Capital | 2.4902 | 1099653 | 1099653 | 2023-02-28 | HIGH |
Barclays Capital Inc. | Research Firm | 2.4441 | 1079256 | 1079256 | 2022-12-31 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.8331 | 809475 | 6376 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 1.7469 | 771421 | 311927 | 2022-12-31 | MED |
Millennium Management LLC | Hedge Fund | 1.7372 | 767121 | 767121 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7218 | 760307 | 22829 | 2022-12-31 | LOW |
Assenagon Asset Management S.A. | Investment Advisor | 1.4329 | 632749 | 18388 | 2022-12-31 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.3734 | 606488 | -55881 | 2022-12-31 | LOW |
Barclays Bank PLC | Investment Advisor | 1.2142 | 536191 | 9424 | 2022-12-31 | MED |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.1107 | 490488 | 490488 | 2022-12-31 | MED |
AQR Capital Management, LLC | Investment Advisor/Hedge Fund | 1.099 | 485298 | 485298 | 2022-12-31 | LOW |
UBS O'Connor LLC | Hedge Fund | 1.0691 | 472102 | 250061 | 2022-12-31 | HIGH |
Medical Strategy GmbH | Investment Advisor | 0.8716 | 384873 | 0 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.8343 | 368413 | 368413 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.8292 | 366178 | 289713 | 2022-12-31 | HIGH |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Eiger Biopharma Company profile
Om Eiger Biopharma
Eiger BioPharmaceuticals, Inc. er en biofarmaceutisk virksomhed i den kommercielle fase. Selskabet er fokuseret på udvikling og markedsføring af lægemidler mod alvorlige sygdomme. Selskabets førende kliniske programmer er fokuseret på udvikling af behandlinger mod Hepatitis Delta Virus (HDV), den alvorlige form for viral hepatitis. Selskabets kliniske produktkandidater omfatter Lonafarnib (LNF) mod HDV, Peginterferon Lambda (lambda) mod HDV, Avexitid mod post-bariatrisk hypoglykæmi (PBH) og Avexitid mod medfødt hyperinsulinisme (CHI). LNF er en oralt biotilgængelig farnesyleringshæmmer i et klinisk fase III-forsøg til behandling af HDV-infektion. Lambda er et interferon (IFN) i den sene fase af type III, som stimulerer immunresponser, der er afgørende for udviklingen af værtsbeskyttelse under virusinfektioner. Avexitide er et peptid, som er under udvikling til behandling af PBH. Avexitide er til behandling af medfødt hyperinsulinisme (CHI), en pædiatrisk stofskiftesygdom.
Industry: | Biotechnology & Medical Research (NEC) |
2155 Park Blvd
PALO ALTO
CALIFORNIA 94306-1543
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com